Alan Ashworth
0000-0003-1446-7878
Publication & Citation Trends
Publications
0 total
The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature OA
Cited by 26
Semantic Scholar
An Inducible Cre Mouse with Preferential Activity in Vascular Smooth Muscle Evades a Previously Lethal Intestinal Phenotype OA
Cited by 1
Semantic Scholar
Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression OA
Cited by 14
Semantic Scholar
Validation of anti-correlated TGFβ signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy. OA
Cited by 10
Semantic Scholar
Complete sequencing of the mouse pseudoautosomal region, the most rapidly evolving ‘chromosome’ OA
Cited by 6
Semantic Scholar
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. OA
Cited by 249
Semantic Scholar
Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer
Cited by 7
Semantic Scholar
A whole genome CRISPR screen identifies AHR loss as a mechanism of PARP7 inhibitor resistance. OA
Cited by 10
Semantic Scholar
ATR Inhibitors and Paclitaxel in Melanoma OA
Cited by 6
Semantic Scholar
ADP-ribosyltransferases, an update on function and nomenclature OA
Cited by 260
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(200)
CRISPR and Genetic Engineering
(128)
DNA Repair Mechanisms
(116)
Cancer Genomics and Diagnostics
(77)
Epigenetics and DNA Methylation
(63)
Affiliations
Scripps Research Institute
University of London
National Health Service
Queen's University Belfast
Merck & Co., Inc., Rahway, NJ, USA (United States)